Exhibit 99.1
FOR IMMEDIATE RELEASE
NanoString Technologies Releases Fourth Quarter and Full Year 2013
Financial Results and Provides 2014 Outlook
- Strong Q4 2013 Revenue Growth of 56% Year over Year -
- Record Q4 2013 Instrument Revenue of $5.3 Million, Up 109% Year over Year -
- Full Year Total Revenue of $31.4 Million, Up 37% Year over Year -
SEATTLE – February 26, 2014 – NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the three and twelve months ended December 31, 2013.
Highlights of the fourth quarter include:
| • | Total revenue of $10.1 million, 56% year-over-year growth |
| • | Instrument revenue of $5.3 million, 109% year-over-year growth |
| • | Adoption of ProsignaTM Breast Cancer Assay by leading US clinical labs and cancer centers |
| • | Commercial launch of nCounter® Dx Analysis System with FLEX configuration with five systems sold in the US |
| • | Publication of the second clinical validation study for Prosigna in Annals of Oncology, the journal of the European Society of Medical Oncology |
“Our strong year-end results and recent accomplishments position NanoString to continue executing on our strategy to become an indispensable part of cancer research and treatment. During the fourth quarter we delivered record revenue and instrument growth,” said President and Chief Executive Officer, Brad Gray. “We are dramatically expanding our addressable market into clinical laboratories, with commercial launches underway of our nCounter Dx Analysis system with FLEX configuration, nCounter ElementsTM General Purpose Reagents, and our Prosigna Breast Cancer Assay. We recently completed a financing which brought approximately $57 million in net proceeds to the company, bolstering our capital resources to fund our growth objectives.”
Fourth Quarter Financial Results
Revenue for the three months ended December 31, 2013 rose 56% to $10.1 million, from $6.5 million for the fourth quarter of 2012. Instrument revenue was $5.3 million, up 109% from the prior year period. Consumables revenue, including in-vitro diagnostic kits, was $4.4 million for the fourth quarter of 2013, 19% higher than in the comparable 2012 quarter.
Gross margin was 52% for the fourth quarter of 2013 compared to 49% for the prior year period. The increase was largely due to manufacturing efficiencies from increasing scale, partially offset by a significant shift in product mix toward instrument revenue.
Research and development expense increased to $4.5 million for the fourth quarter of 2013, versus
$3.4 million for the fourth quarter of 2012, reflecting increased investment in technology development. Selling, general and administrative expense was $9.1 million for the fourth quarter of 2013 compared to $4.9 million for the prior year period. The increase reflects Prosigna launch costs, investments to expand the existing commercial organization and other increased corporate costs, including those related to the transition to becoming a public company.
Net loss attributable to common stockholders for the three months ended December 31, 2013 was $8.8 million, or a loss of $0.60 per diluted share, compared with $7.9 million, or a loss of $19.85 per diluted share, for the fourth quarter of 2012. Non-GAAP net loss for the three months ended December 31, 2013 was $7.5 million, or a loss of $0.51 per diluted share, compared with non-GAAP net loss of $4.4 million, or a loss of $0.53 per diluted share, for the prior year period (see accompanying table for reconciliation of GAAP and non-GAAP financial measures).
Full Year 2013 Financial Results
Revenue for 2013 rose 37% to $31.4 million, from $23.0 million for 2012. Instrument revenue was $13.0 million, up 48% from the prior year. Consumables revenue, including in-vitro diagnostic kits, was $16.8 million for 2013, 29% higher than for the prior year.
Gross margin increased to 52% for 2013 compared to 46% for the prior year. Research and development expense was $15.0 million for 2013, versus $11.6 million for 2012. Selling, general and administrative expense was $29.9 million for 2013 compared to $15.5 million for the prior year.
Net loss attributable to common stockholders for 2013 was $33.9 million, or a loss of $4.44 per diluted share, compared with $25.2 million, or a loss of $71.10 per diluted share, for 2012. Non-GAAP net loss for 2013 was $25.6 million, or a loss of $2.14 per diluted share, compared with non-GAAP net loss of $13.8 million, or a loss of $1.72 per diluted share, for the prior year (see accompanying table for reconciliation of GAAP and non-GAAP financial measures).
The company ended 2013 with $42.7 million of cash, cash equivalents, and short-term investments.
NanoString’s Outlook for 2014 Includes:
| • | Total revenue in the range of $45.0 to $50.0 million, representing an approximate increase of 43% to 59% over 2013 |
| • | Gross margin in the range of 55% to 58% |
| • | Operating expenses in the range of $70.0 to $75.0 million |
| • | Net operating loss in the range of $40.0 to $50.0 million |
Conference Call
Management will host an investment community conference call today beginning at 1:30 pm PT / 4:30 pm ET to discuss these results and answer questions. Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers, or from the webcast link in the investor relations section of the Company’s website at: www.nanostring.com. The webcast will be available on the company’s website for 14 days following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 360 peer-
reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company’s technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company’s diagnostics business. The nCounter Dx Analysis System is FDA 510(k) cleared for use with the Prosigna Breast Cancer Prognostic Gene Signature Assay. To date, it has not been cleared by the FDA for other indications or for use with other assays.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, nCounter Elements and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.
For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our ability to successfully execute on our strategy, our expectations regarding the launch and impact of new products, future growth and long-term profitability, and our estimated 2014 operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
Use of Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures in this release. Management of the company believes that these non-GAAP financial measures, considered together with GAAP financial information, provide useful information for investors by excluding certain non-cash and other income and expense that are not indicative of the company’s core operating performance. Reconciliations of the non-GAAP financial measures used in this release to the most directly comparable GAAP measures for the respective periods can be found in “Reconciliation of GAAP to Non-GAAP Financial Information” immediately following the financial tables. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.
Investor Contact:
Lynn Pieper of Westwicke Partners
For NanoString Technologies
lynn.pieper@westwicke.com
415-202-5678
Media Contact:
Nicole Litchfield
For NanoString Technologies
nicole@bioscribe.com
415-793-6468
— Financial Tables Follow —
NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Revenue: |
||||||||||||||||
| Instruments |
$ | 5,281 | $ | 2,524 | $ | 12,995 | $ | 8,786 | ||||||||
| Consumables |
4,262 | 3,711 | 16,642 | 13,036 | ||||||||||||
| In-vitro diagnostic kits |
140 | — | 181 | — | ||||||||||||
| Service revenue |
437 | 258 | 1,585 | 1,151 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenue |
10,120 | 6,493 | 31,403 | 22,973 | ||||||||||||
| Costs and expenses: |
||||||||||||||||
| Cost of revenue |
4,821 | 3,285 | 15,009 | 12,361 | ||||||||||||
| Research and development |
4,510 | 3,382 | 14,979 | 11,635 | ||||||||||||
| Selling, general and administrative |
9,090 | 4,898 | 29,912 | 15,486 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total costs and expenses |
18,421 | 11,565 | 59,900 | 39,482 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(8,301 | ) | (5,072 | ) | (28,497 | ) | (16,509 | ) | ||||||||
| Other income (expense): |
||||||||||||||||
| Interest income |
40 | 4 | 68 | 21 | ||||||||||||
| Interest expense |
(530 | ) | (253 | ) | (1,942 | ) | (804 | ) | ||||||||
| Revaluation of preferred stock warrant liability |
— | (537 | ) | 1,156 | (387 | ) | ||||||||||
| Other income (expense) |
(36 | ) | (3 | ) | (66 | ) | (29 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total other income (expense) |
(526 | ) | (789 | ) | (784 | ) | (1,199 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
(8,827 | ) | (5,861 | ) | (29,281 | ) | (17,708 | ) | ||||||||
| Accretion of mandatorily redeemable convertible preferred stock |
— | (2,018 | ) | (4,653 | ) | (7,533 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss attributable to common stockholders |
$ | (8,827 | ) | $ | (7,879 | ) | $ | (33,934 | ) | $ | (25,241 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share, basic and diluted |
$ | (0.60 | ) | $ | (19.85 | ) | $ | (4.44 | ) | $ | (71.10 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Shares used in calculating basic and diluted net loss per share |
14,617 | 397 | 7,643 | 355 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
NANOSTRING TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
| December 31, 2013 |
December 31, 2012 |
|||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 9,941 | $ | 21,692 | ||||
| Short-term investments |
32,715 | — | ||||||
| Accounts receivable, net |
8,331 | 3,322 | ||||||
| Inventory |
6,750 | 5,380 | ||||||
| Prepaid expenses and other |
2,999 | 1,320 | ||||||
|
|
|
|
|
|||||
| Total current assets |
60,736 | 31,714 | ||||||
| Deferred offering costs |
29 | 1,765 | ||||||
| Property and equipment, net |
3,065 | 3,674 | ||||||
| Other assets |
542 | 253 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 64,372 | $ | 37,406 | ||||
|
|
|
|
|
|||||
| LIABILITIES, MANDATORILY REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 3,354 | $ | 2,865 | ||||
| Accrued liabilities |
7,088 | 4,481 | ||||||
| Long-term debt, current portion |
6,136 | 2,789 | ||||||
| Other |
2,052 | 1,642 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
18,630 | 11,777 | ||||||
| Long-term debt, net of current portion |
12,157 | 9,970 | ||||||
| Preferred stock warrant liability |
— | 3,532 | ||||||
| Other non-current liabilities |
2,116 | 2,265 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
32,903 | 27,544 | ||||||
| Mandatorily redeemable convertible preferred stock |
— | 103,622 | ||||||
| Total stockholders’ equity (deficit) |
31,469 | (93,760 | ) | |||||
|
|
|
|
|
|||||
| Total liabilities, mandatorily redeemable convertible preferred stock and stockholders’ equity (deficit) |
$ | 64,372 | $ | 37,406 | ||||
|
|
|
|
|
|||||
NANOSTRING TECHNOLOGIES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(in thousands, except per share amounts)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Net loss attributable to common stockholders (GAAP) |
$ | (8,827 | ) | $ | (7,879 | ) | $ | (33,934 | ) | $ | (25,241 | ) | ||||
| Accretion of mandatorily redeemable convertible preferred stock |
— | 2,018 | 4,653 | 7,533 | ||||||||||||
| Change in the fair value of preferred stock warrant liability |
— | 537 | (1,156 | ) | 387 | |||||||||||
| Stock-based compensation expense |
379 | 179 | 1,145 | 745 | ||||||||||||
| Depreciation and amortization |
419 | 480 | 1,779 | 1,947 | ||||||||||||
| Interest expense |
530 | 253 | 1,942 | 804 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss (non-GAAP) |
$ | (7,499 | ) | $ | (4,412 | ) | $ | (25,571 | ) | $ | (13,825 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Shares used in calculating basic and diluted net loss per share (GAAP) |
14,617 | 397 | 7,643 | 355 | ||||||||||||
| Shares of common stock issuable upon conversion of mandatorily redeemable convertible preferred stock |
— | 7,949 | 4,280 | 7,663 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Shares used in calculating basic and diluted net loss per share (non-GAAP) |
14,617 | 8,346 | 11,923 | 8,018 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share, basic and diluted (GAAP) |
$ | (0.60 | ) | $ | (19.85 | ) | $ | (4.44 | ) | $ | (71.10 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share, basic and diluted (non-GAAP) |
$ | (0.51 | ) | $ | (0.53 | ) | $ | (2.14 | ) | $ | (1.72 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||